Examinations: Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
Study summary
Chronic inflammatory rheumatism and inflammation can increase the risk of cardiovascular problems. Indeed, these diseases can increase the risk of myocardial infarction. The objective of this project is a better understanding and preventing the risk of cardiovascular problems in chronic inflammatory rheumatism through the study on the long-term flexibility of the arteries, blood markers of cardiovascular risk and muscle mass.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Being older than 18 years
* Have rheumatoid arthritis or spondyloarthritis (ankylosing spondylitis, psoriatic arthritis)
* Receive first conventional DMARD or biological treatment (anti-TNF, Abatacept, Tocilizumab, rituximab) for patients with rheumatoid arthritis
* Receive biological treatment (Abatacept, Tocilizumab, rituximab) for patients with rheumatoid arthritis who have failed anti-TNF treatment.
* Receive first NSAID (optionally combined with conventional DMARDs in case of peripheral arthritis) or biological treatment (anti-TNF, Usketinumab) for patients with spondyloarthritis.
* Being subject to a social security scheme
* Have the capacity to give informed consent and to comply with the study requirements
Exclusion Criteria:
* Patient refused to sign the consent form
* Patient under guardianship
* Patient having already been exposed to a biological as part of its pathology
* Patient with chronic disease may interfere with cardiovascular disease either by itself or by treatment history
* For echocardiography high resolution STI: Patients with hypertension, diabetes and cardiovascular history.
* To evaluate the activity of the autonomic nervous system, patients with hypertension, diabetics, with cardiovascular history with a neurological disease, with vasoactive or chronotropic treatments such as beta-blockers, antiarrhythmics, antihypertensives, anxiolytics, antidepressants
* Pregnant or lactating women will be temporarily excluded from the study during the period of pregnancy and breastfeeding.
Primary outcome measure(s)
Change from baseline of the arterial Stiffness — at 6 months, 12 months evaluated by the pulse wave velocity
Change from baseline of resting heart rate — at 6 months, 12 months
Change from baseline of endothelial function — at 6 months, 12 months by Tonometry
Change from baseline of intima-media thickness and carotid and femoral atheroma — at 5 years
Change from baseline of autonomic nervous system activity — at 6 months, 12 months
Change from baseline of regional myocardial function — at 6 months, 12 months
Change from baseline of other markers of cardiovascular risk — at 6 months, 12 months troponin, NT\_proBNP, adipocytokines, MCP-1, assymetric dimethylaarginine, angiopoietin-2, anti apo A-1, IL-6, IL-17
Change from baseline of an abdominal aortic calcification score (DEXA) — at 6 months, 12 months
Change from baseline of hand muscle strength (Handgrip) — at 6 months, 12 months
Change from baseline of energy expenditure and physical activity in usual living conditions — at 6 months, 12 months by Android application on smartphone (eMeetingSearch)
Change from baseline of food habits — at 6 months, 12 months French FFQ questionnaire
Change from baseline of body composition — at 6 months, 12 months DEXA, pQCT
Change from baseline of inflammatory rheumatism — at 6 months, 12 months by the doctor in charge of the patient
Change from baseline of depression (HAD) — at 6 months, 12 months
Change from baseline of fibromyalgia (FIRST) — at 6 months, 12 months
Change from baseline of the frequency of comorbidities during inflammatory rheumatism — at 6 months, 12 months
Trial sites (1)
Facility
City
Region
Status
CHU de Clermont-Ferrand
Clermont-Ferrand
Auvergne
More University Hospital, Clermont-Ferrand trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
